Pedram Razavi

33PUBLICATIONS
275CO-AUTHORS
Molecular targetsEnvironmental epidemiologyCancer geneticsHaematological tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (33)

|Sep 09, 2026
ERBB2 Activating Mutations Promote Enhanced Internalization and Activity of Trastuzumab Deruxtecan in HER2-non-amplified Metastatic Breast Cancer.

|May 05, 2026
Benralizumab for Eosinophil-Related Cutaneous Adverse Events of Anticancer Therapy: A Phase II Trial.

|Mar 04, 2026
Homologous recombination deficiency and hemizygosity drive resistance in breast cancer.

Anton Safonov, Minna Lee, David N Brown

|Feb 23, 2026
Evolution of oncogene amplification across 86,000 cancer cell genomes.

Jake June-Koo Lee, Sohrab Salehi, Matthew A Myers

|Nov 10, 2025
Machine Learning-Based Prediction of Distant Recurrence Risk and Ribociclib Treatment Effect in HR+/HER2- Early Breast Cancer Using Real-World and NATALEE Data.

Frederick M Howard, Peter A Fasching, Cesar A Santa-Maria

|Nov 10, 2025
Trastuzumab Deruxtecan Resistance via Loss of HER2 Expression and Binding.

Wanyi Chen, Avantika Gupta, Nicholas Mai

Pageof 6

Frequent Collaborators

18 joint publications

Sarat Chandarlapaty

10 joint publications

Jorge S Reis-Filho

9 joint publications

Fresia Pareja

8 joint publications

Bob T Li